home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408a.zip
/
M9480027.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
2KB
|
37 lines
Document 0027
DOCN M9480027
TI Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate
immunogens.
DT 9410
AU Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S;
Rivetna M; Rusiecki VK; Sugg EE; et al; Department of Virus and Cell
Biology, Merck Research; Laboratories, West Point, PA 19486.
SO Vaccine. 1994 Apr;12(5):445-51. Unique Identifier : AIDSLINE
MED/94295251
AB A successful prophylactic human immunodeficiency virus type 1 (HIV-1)
vaccine must elicit an immune response that will prevent establishment
of the persistent viral infection. The only response shown to be
effective in this regard is virus-neutralizing antibody directed against
the viral gp120 hypervariable V3-loop region. Conjugate immunogens,
containing cyclic peptides representing the V3 determinant covalently
bound to a carrier protein, were capable of eliciting virus-neutralizing
antibodies. The consistency of the response was related to peptide size.
The smaller cyclic peptides, expressing relatively conserved sequences
from the V3-loop apex, were poor inducers of neutralizing activity. In
contrast, the largest cyclic peptides mediated neutralizing responses
that were similar to those observed and previously reported for intact
gp120 immunogens. A cyclic synthetic peptide expressing most of the
prototypic HIV-1 MN variant V3 determinant warrants further study as a
potentially effective vaccine immunogen.
DE Amino Acid Sequence Animal AIDS Vaccines/*IMMUNOLOGY Comparative
Study Enzyme-Linked Immunosorbent Assay Haplorhini HIV
Antibodies/BIOSYNTHESIS HIV Envelope Protein gp120/*IMMUNOLOGY
HIV-1/*IMMUNOLOGY Molecular Sequence Data Neutralization Tests
Peptide Fragments/CHEMICAL SYNTHESIS/*IMMUNOLOGY Peptides,
Cyclic/CHEMICAL SYNTHESIS/IMMUNOLOGY Rabbits Vaccines,
Conjugate/IMMUNOLOGY Vaccines, Synthetic/IMMUNOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).